As much as Insider Finacial lacks credibility, if you read the article it is very detailed about the situation. Even if you take the predictions of the future out of it, it is hard not to see the DSMC really screwed up and cytodyn followed the rules. It is hard not to see to superiority of leronlimab over everything else by a mile. It is easy to see the FDA is in a pickle, the data shows it works and if they delay, it is on them. This is a possible bidding war, it is possible we have heard nothing this week because the FDA knows they have a big problem brewing if they do not do the right thing.